MESUPRON® (INN: Upamostat) was successfully licensed to the chinese company Link Health Group and the Israel based RedHill Biopharma Ltd. in 2014. WILEX will not continue the development for this product candidate but will participate on the further development by future milestone payments and royalties.
|Compound Class||Oral small molecule serine protease inhibitor|
|Indications||Currently pancreatic and breast cancer, additional indications including ovarian and colon cancer possible|
|Target||The uPA system has been shown to play a key role in tumour cell invasion and metastasis, as well as in primary tumour growth, of various solid tumours including breast, ovarian, gastric, colon and pancreatic cancer.|
|Mode of Action||Anti-metastatic, non-cytotoxic agent|
|Development Status||WILEX has developed the orally available drug candidate MESUPRON® as a pro-drug of WX-UK1. The drug candidates in the uPA programme, WX-UK1 and MESUPRON®, are the first inhibitors of uPA in oncology trials worldwide. Eight different clinical trials with WX-UK1 and MESUPRON® in several indications were successfully conducted. MESUPRON® met its primary objective of demonstrating efficacy in the proof of concept phase II breast cancer trial.|
|Development Rationale||With oral MESUPRON®, WILEX has developed a drug candidate to inhibit the Urokinase Plasminogen Activator (uPA) system. The uPA programme of WILEX can be considered as a promising new non-cytotoxic approach in cancer therapy to specifically block tumour metastasis in solid cancers.|